Oppenheimer Q2 Review on Cadence Pharma (CADX): Supply Shortage Not Expected From Recall
Tweet
Share
E-mailGet Alerts CADX Hot Sheet
Price: $13.98 --0%
Rating Summary:
2 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 1
Rating Summary:
2 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 1
Join SI Premium – FREE
Oppenheimer maintains a 'Perform' on Cadence Pharma (NASDAQ: CADX).
Analyst, Christopher Holterhoff, said, "On 8/2, CADX reported 2Q12 adj. EPS of ($0.19), above our ($0.25) estimate, as lower than expected revenues were more than offset by lower than expected operating costs. We highlight that OFIRMEV revenues grew 38% to ~$11.1M (vs. our $12.8M estimate and consensus of $10.9M) during the quarter. While OFIRMEV sales have exhibited some positive trends, we estimate these to be reflected in the current share price. We lower our 3Q12 OFIRMEV sales estimates (from $19.6M to $14.2M) on updated management guidance. Importantly, we believe the current 2013 consensus number for OFIRMEV ($97.2M), which is above our $77.2M estimate, could prove to be too aggressive."
FY12 EPS estimate raised from (0.73) to (0.57) and FY13 from (0.63) to (0.33)
For an analyst ratings summary and ratings history on Cadence Pharma click here. For more ratings news on Cadence Pharma click here.
Shares of Cadence Pharma closed at $4.07 yesterday.
Analyst, Christopher Holterhoff, said, "On 8/2, CADX reported 2Q12 adj. EPS of ($0.19), above our ($0.25) estimate, as lower than expected revenues were more than offset by lower than expected operating costs. We highlight that OFIRMEV revenues grew 38% to ~$11.1M (vs. our $12.8M estimate and consensus of $10.9M) during the quarter. While OFIRMEV sales have exhibited some positive trends, we estimate these to be reflected in the current share price. We lower our 3Q12 OFIRMEV sales estimates (from $19.6M to $14.2M) on updated management guidance. Importantly, we believe the current 2013 consensus number for OFIRMEV ($97.2M), which is above our $77.2M estimate, could prove to be too aggressive."
FY12 EPS estimate raised from (0.73) to (0.57) and FY13 from (0.63) to (0.33)
For an analyst ratings summary and ratings history on Cadence Pharma click here. For more ratings news on Cadence Pharma click here.
Shares of Cadence Pharma closed at $4.07 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Upgrades Husqvarna AB (HUSQB:SS) to Buy
- Baird Downgrades Hibbett Sports (HIBB) to Neutral
- Deutsche Bank Downgrades WNS Limited (WNS) to Hold
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS ViewSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
